Pfizer-BioNTech said in a statement on July 8 that data from studies looking at the effects of a booster shot of its COVID-19 vaccine are “encouraging.” The companies are testing a third dose of its two-dose regimen—currently permitted by the U.S. Food and Drug Administration (FDA) under an emergency use authorization—to see how effective the … Read more
0000000000000 Welcome to COVID Questions, TIME’s advice column. We’re trying to make living through the pandemic a little easier, with expert-backed answers to your toughest coronavirus-related dilemmas. While we can’t and don’t offer medical advice—those questions should go to your doctor—we hope this column will help you sort through this stressful and confusing time. Got … Read more
The Olympics and COVID-19 were never going to be compatible. The cardinal rule when it comes to controlling an infectious disease is to limit the contact people have with one another. Yet the very essence of the two weeks of competition, which begin on July 23 in Tokyo, is to invite the world to meet, greet … Read more
Scientists were critical of the announcement, pointing to evidence that the current two-dose regimen is powerfully effective against the coronavirus. View original article Contributor: Apoorva Mandavilli
The revised label clarifies that the drug, called Aduhelm, is intended for patients with early-stage disease — the population that participated in clinical trials of the drug. View original article Contributor: Laurie McGinley
The findings suggest recovery from the pandemic may take a long time and could affect people’s view of their relationships over time. View original article Contributor: Reed Abelson
Limitless CBD Creating Alternative Health and Wellness Products Using CBD Influencive >View original article Contributor:
American intelligence agencies are tapping outside expertise as they wrestle with mysteries like the coronavirus and U.F.O.s that are as much about science as they are about espionage. View original article Contributor: Julian E. Barnes
The states, including Massachusetts and New York, agreed to drop opposition to the bankruptcy organization plan of the company, the maker of OxyContin. View original article Contributor: Jan Hoffman
American intelligence agencies are tapping outside expertise as they wrestle with mysteries that are as much about science as they are about espionage. View original article Contributor: Julian E. Barnes